Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies
- 1 March 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (5) , 995
- https://doi.org/10.1200/jco.2000.18.5.995
Abstract
PURPOSE: To characterize the pharmacokinetics of nelarabine (506U78), the water-soluble prodrug of 9-beta-d-arabinofuranosyl guanine (ara-G), and ara-G in pediatric and adult patients with refractory hematologic malignancies. Ara-G is phosphorylated within leukemic cells to form ara-G triphosphate (ara-GTP), which acts to terminate DNA chain elongation, resulting in cell death. PATIENTS AND METHODS: The pharmacokinetics of nelarabine and/or ara-G were evaluated in 71 patients (25 pediatric and 46 adult patients) on the first day of therapy. Blood was collected at specified times for the determination of plasma nelarabine and ara-G concentrations. RESULTS: There were no statistically significant differences in the pharmacokinetics of nelarabine between any of the groups of patients. The harmonic mean half-life (t1/2) of nelarabine in pediatric and adult patients was 14.1 minutes and 16.5 minutes, respectively. The maximum concentrations (Cmax) of ara-G occurred at or near the end of the nelarabine infusion. The Cmax of ara-G ranged from 11.6 μmol/L to 308.7 μmol/L at nelarabine doses of 5 to 75 mg/kg and was linearly related to the nelarabine dose. No statistically significant differences were noted for the pharmacokinetic parameter estimates of ara-G between adult male and female patients. In children versus adults, the dose-normalized Cmax, time of the Cmax, and the steady-state volume of distribution of ara-G were similar. However, the clearance of ara-G was higher in pediatric patients (0.312 L·h−1·kg−1) as compared with adult patients (0.213 L·h−1·kg−1) (P < .001). The t1/2 of ara-G was shorter in pediatric patients as compared with adult patients (2.1 hours v 3.0 hours; P < .01). CONCLUSION: Nelarabine is an effective prodrug of ara-G, allowing systemic concentrations of ara-G that result in clinical activity.Keywords
This publication has 16 references indexed in Scilit:
- PHARMACOLOGIC PURGING OF MALIGNANT T CELLS FROM HUMAN BONE MARROW USING 9-β-D-ARABINOFURANOSYLGUANINETransplantation, 1991
- Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liverBiochemical Pharmacology, 1989
- Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts.Journal of Clinical Investigation, 1984
- An enzymic synthesis of purine d-ArabinonucleosidesCarbohydrate Research, 1981
- Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines.Proceedings of the National Academy of Sciences, 1979
- Fitting straight lines when both variables are subject to errorLife Sciences, 1978
- Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s)Proceedings of the National Academy of Sciences, 1977
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITYThe Lancet, 1975
- Synthesis of 9-β-D-Arabinofuranosylguanine*Biochemistry, 1964